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BACKGROUND: High-sensitivity cardiac troponin assays may improve the diagnosis of myocardial infarc-
tion but increase the detection of elevated cardiac troponin in patients without acute coronary syndrome.
METHODS: In a prospective cohort study, we evaluated the prevalence, determinants, and outcome of patients
with elevated cardiac troponin attending the emergency department without suspected acute coronary syn-
drome. We measured high-sensitivity cardiac troponin in 918 consecutive patients attending the emergency
department without suspected acute coronary syndrome who had blood sampling performed by the attending
clinician. Elevated high-sensitivity cardiac troponin I was defined as concentrations above the sex-specific
99th percentile threshold. Clinical demographics, physiological measures, and all-cause mortality at 1 year
associated with elevated high-sensitivity cardiac troponin concentrations were recorded.
RESULTS: Elevated cardiac troponin concentration occurred in 114 (12.4%) patients, of whom 2 (0.2%), 3
(0.3%), and 109 (11.9%) were adjudicated as type 1 myocardial infarction, type 2 myocardial infarction, and
myocardial injury, respectively. Elevated troponin concentrations were associated with increasing age, wors-
ening renal function, multimorbidity, and adverse physiology. Across a total of 912 patient-years follow-up,
cardiac troponin concentration was a strong predictor of death (hazard ratio [HR] 1.26 per 2-fold increase,
95% confidence interval [CI] 1.06 to 1.49) independent of age, sex, multimorbidity, and adverse physiology.
CONCLUSIONS: High-sensitivity cardiac troponin concentrations were elevated in 1 in 8 consecutive patients
without suspected acute coronary syndrome attending the emergency department and were associated with
increasing age, multimorbidity, adverse physiology, and death. Elevated cardiac troponin in unselected patients
predominantly reflects myocardial injury rather than myocardial infarction.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license. (http://
creativecommons.org/licenses/by/4.0/)  The American Journal of Medicine (2019) 132:110.e9−110.e22
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1016/j.amjmed.2018.10.002BACKGROUND
Although cardiac troponin is integral to the diagnosis of myo-
cardial infarction,1 the approach to testing varies markedly
across different healthcare systems.2-4 In some centers, cardiac
troponin is used as a screening test, irrespective of the clinical
presentation.4 In a representative sample of patients attending
emergency departments in the United States, cardiac troponin
was measured in 1 in 5 patients.5 Moreover, in more than half
of those who were subsequently hospitalized, one-third of
patients did not have any cardiac symptoms.5article under the CC BY license.
Lee et al High-Sensitivity Cardiac Troponin in the Emergency Department 110.e10We recently assessed the variation in patient selection
for high-sensitivity troponin testing between emergencyCLINICAL SIGNIFICANCE
 Elevated high-sensitivity cardiac troponin con-
centration is common in patients presenting to
the emergency department without suspected
acute coronary syndrome.
 The vast majority of these elevated cardiac tro-
ponin concentration reflects myocardial injury
rather than myocardial infarction.
 Cardiac troponin concentration is strongly asso-
ciated with age, comorbidity, adverse physiol-
ogy at presentation, and worse outcomes.departments and its impact on
the diagnosis of type 1 myo-
cardial infarction.6 Compared
to the United Kingdom, car-
diac troponin testing was per-
formed more widely in the
United States, resulting in a
much lower prevalence (4.2%
vs 14.5%) and positive pre-
dictive value (16.4% vs
59.7%) for type 1 myocardial
infarction in those patients
tested.6 These findings high-
light the importance of patient
selection to optimize the diag-
nostic utility of cardiac tropo-
nin testing for type 1myocardial infarction.6
High-sensitivity cardiac troponin assays have been
widely implemented in many countries and have improved
the diagnosis of myocardial infarction1,7 and risk stratifica-
tion in patients with suspected acute coronary syndrome.7
However, the high-sensitivity test also increases the detec-
tion of elevated cardiac troponin in many cardiac and non-
cardiac conditions that are unrelated to acute coronary
syndrome.8-10 As such, the introduction of a high-sensitiv-
ity cardiac troponin assay may contribute to diagnostic
uncertainty, particularly in healthcare settings where indis-
criminate testing is high.2,5
Here, we aim to evaluate the prevalence of elevated
high-sensitivity cardiac troponin concentrations in consecu-
tive patients without suspected acute coronary syndrome in
emergency department and describe the determinants and
clinical associations of high-sensitivity cardiac troponin
concentrations.METHODS
Study Population
We prospectively identified consecutive patients presenting
to the Emergency Department at the Royal Infirmary of
Edinburgh, Scotland, between July 5 and 16, 2013. The
Royal Infirmary of Edinburgh Emergency Department
serves a population of more than 1 million across the south
east of Scotland. It is an adult tertiary emergency depart-
ment, serving as regional referral center for trauma, sur-
gery, and cardiology, assessing approximately 120,000
patients annually.
All patients without suspected acute coronary syndrome
in whom the attending clinician performed blood sampling
at presentation and did not request a cardiac troponin test
were eligible for inclusion in this analysis (Supplementary
Figure 1). Excess serum from blood samples were used to
measure high-sensitivity cardiac troponin I. These resultswere not reported to the attending clinician to guide clinical
care. Patients who had a previous admission during thestudy period, or in whom there
was insufficient sample vol-
ume for analysis, were
excluded. This study was per-
formed with approval from
the National Health Service
Research Scotland BioRe-
source and Tissue Governance
Unit in accordance with the
Declaration of Helsinki. As
surplus material was acellular,
individual consent from each
patient was not sought. How-
ever, to comply with our gov-
ernance policy, we used an
encrypted identification num-
ber for each individual tropo-nin result measured on excess serum to ensure that they
were never linked to patient identifiers. We have employed
a similar approach for previous clinical trials and cohort
studies conducted in this manner.6-8,11-12Troponin Assay
Excess serum was analyzed using the ARCHITECTSTAT
high-sensitive troponin I assay (Abbott Laboratories,
Abbott Park, IL, USA). This assay has a limit of detection
of 1.2 ng/L and the inter-assay CV <10% at 4.7 ng/L. The
99th percentile upper reference limit (URL) is 34 ng/L in
men and 16 ng/L in women.12,13Clinical Characteristics
Baseline clinical characteristics and investigations were
obtained from a standardized electronic patient record
(TrakCare, InterSystems Corporation, Cambridge, MA,
USA) as previously described.8,12,14 These included medi-
cal history, cardiovascular risk factors, presenting symp-
toms, medication use, and electrocardiographic
abnormalities. Hyperlipidemia and hypertension were
defined as a documented history of the condition or by the
respective use of lipid-lowering or antihypertensive medi-
cations. The National Early Warning Score (NEWS) was
calculated for patients incorporating six simple physiologi-
cal variables (ie pulse rate, blood pressure, temperature,
oxygen saturations, level of consciousness, and respiratory
rate measured at admission; Supplementary Table 1).15Classification of Myocardial Injury and
Myocardial Infarction
Elevated cardiac troponin concentration was defined using
sex-specific thresholds at the 99th percentile URL.1,7,16
Two cardiologists reviewed all clinical information inde-
pendently, including noninvasive and invasive investiga-
tions and outcomes from admission to 30 days as described
110.e11 The American Journal of Medicine, Vol 132, No 1, January 2019previously.7,11,12 Patients with elevated cardiac troponin
were classified according to the universal definition of myo-
cardial infarction.7,12 Type 1 myocardial infarction was
defined in which myocardial necrosis occurred in the con-
text of a presentation with symptoms suggestive of an acute
coronary syndrome or evidence of myocardial ischemia on
the electrocardiogram. Patients with myocardial necrosis
and symptoms or signs of myocardial ischemia as a result
of increased oxygen demand or decreased supply (eg tachy-
arrhythmia, hypotension, or anemia) due to an alternative
diagnosis were classified as type 2 myocardial infarction.
Myocardial injury was defined as elevated cardiac troponin
concentration without signs or symptoms of myocardial
ischemia. A third adjudicator resolved any discrepancies in
adjudication through in-depth review of source documents.Clinical Outcomes
Death from any cause was identified from regional and
national registries including the General Register of Scot-
land,17 allowing capture of all deaths in the hospital and in
the community, ensuring complete follow-up in all patients.
Patients who were not residents of Scotland were censored
at the time of discharge.Statistical Analysis
Patients were divided into four groups a priori: those
patients with cardiac troponin concentrations >99th percen-
tile URL (men >34 ng/L and women >16 ng/L; group 4)
and the remaining patients separated into three equal ter-
tiles (groups 1-3). The distribution of cardiac troponin dif-
fered in men and women (Supplementary Figure 2), and
therefore, they were grouped separately. Summary statistics
were derived for all patients stratified by these four groups.
Continuous variables were compared using parametric and
nonparametric tests as appropriate.
We calculated the prevalence of elevated cardiac tropo-
nin across the whole population and stratified by age, sex,
known ischemic heart disease, renal function, and comor-
bidities (eg hypertension, ischemic heart disease, peripheral
vascular disease, diabetes mellitus, and cerebrovascular dis-
ease). Where the prevalence was close to 0%, we calculated
the 95% confidence interval (CI) using a Bayesian approach
by sampling from a binomial likelihood with a noninforma-
tive Jeffreys prior (ß-distribution shape parameters both
equal to 0.5).
Factors associated with elevated cardiac troponin con-
centrations were modeled using logistic regression with
adjustment for age, sex, renal function, multimorbidity (eg,
hypertension, diabetes mellitus, ischemic heart disease,
cerebrovascular disease, or peripheral vascular disease) and
NEWS. Occurrence of death was modelled using a Cox-
proportional hazards regression with troponin (natural log)
as the explanatory variable both as a single variable and
after adjusting for age, sex, renal function, and NEWS. We
examined the linearity of the association between troponin
concentration and risk of death using Cox-proportionalregression models with smoothing splines for high-sensitiv-
ity cardiac troponin concentrations and 4 degrees of free-
dom. Cox-regression models were constructed and
evaluated for the proportional hazards assumption. Analy-
ses were performed in R Version 3.5.1 Statistical signifi-
cance was taken as a two-sided P < 0.05.RESULTS
Study Population
There were 3619 attendances to the Emergency Department
across the study period, and blood samples were obtained as
part of routine clinical care in 1103 (Supplementary Figure
1). Prior inclusion in the study or insufficient blood sample
for analysis excluded 49 patients. The attending clinician
requested cardiac troponin in 12.9% (n=136) of all patients
who had blood drawn. Patients who had a troponin test
requested were more likely to have presented to the emer-
gency department with chest pain (79.4% vs 8.3%, P-value
<0.001), have cardiac risk factors, and past medical history
of ischemic heart disease (Supplementary Table 2). These
patients (n = 136) were excluded, resulting in a final study
population of 918 patients (Supplementary Figure 1).Prevalence of Elevated Cardiac Troponin
Concentration
The prevalence of elevated cardiac troponin was 12.4%
(n=114/918). Two (0.2%) and 3 (0.3%) patients with ele-
vated cardiac troponin concentrations were adjudicated as
having had type 1 and type 2 myocardial infarction, respec-
tively, with the remaining 109 patients adjudicated as hav-
ing myocardial injury (11.9%) (Figure 1, Supplementary
Table 3).Determinants of Elevated Cardiac Troponin
Concentration
Patients with elevated cardiac troponin (group 4) were older
(78 § 17 vs 34 § 13 years, P < 0.001) and more likely to
have comorbid conditions than those with the lowest car-
diac troponin concentrations (group 1) (Table 1). Patients
with elevated cardiac troponin were also more likely to
have adverse physiology (medium or high-risk NEWS,
19.5% vs 2.4%, P<0.001), lower hemoglobin concentra-
tions (12.1§2.4 vs 13.7§1.6 g/dL, P<0.001), and higher
creatinine concentrations (1.30§1.00 vs 0.80§0.16 mg/
dL).
On logistic regression modeling, both age (model 1:
odds ratio [OR] 2.13, 95% CI 1.78 to 2.62 per 10-year
increment) and comorbidity (model 2: OR 10.11, 95% CI
4.3 to 23.81 for 3 or more comorbidities compared to none)
were strongly associated with elevated cardiac troponin
after adjusting for sex, renal function, and NEWS (Table
2). When adjusting for both age and comorbidity, age
remained a powerful determinant of elevated cardiac
Figure 1 Prevalence of elevated cardiac troponin concentration in the emergency department stratified by gender, age, comorbidity,
and renal function in those patients in whom cardiac troponin was not requested by the attending clinician.
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years increment, P<0.001).Outcomes of Patients with Elevated Cardiac
Troponin Concentration
Most patients with elevated cardiac troponin were admitted
into hospital (96/114, 84.2%). Patients with elevated car-
diac troponin (group 4) were more likely to have died at 30
days and 1 year than those with the lowest cardiac troponin
concentrations (group 1) (19.3% vs 0.6% at 30 days, P-
value (log-rank) <0.001 and 37.7% vs 1.9% at 1 year,
P<0.001; Table 1 and Figure 2A). With time to event anal-
ysis, across a total of 912 patient-years of follow-up, car-
diac troponin concentration was a strong predictor of death
(hazard ratio [HR] 1.62, 95% CI 1.50 to 1.75, p<0.001 for
every doubling of troponin concentration; Figure 2A and
2B). This association attenuated after adjusting for age,
sex, multimorbidity, adverse physiology, and renal function
(HR 1.26, 95% CI 1.06 to 1.49, P=0.003 for every doubling
of troponin concentration). There was a near linear relation-
ship between troponin concentration at presentation and
risk of death (Figure 2B). The proportional hazards assump-
tion for the Cox model was met (P=0.664).DISCUSSION
Given the increasing use of high-sensitivity cardiac tropo-
nin assays in clinical practice and the potential diagnostic
challenges that elevated troponin concentrations may pose,
we evaluated the prevalence and factors associated with an
elevated cardiac troponin concentration in consecutive
patients to the Emergency Department who did not have
suspected acute coronary syndrome in whom the attending
clinician performed blood sampling. We make several
important observations. First, in our center, approximately
1 in every 8 patients without suspected acute coronary syn-
drome who underwent blood sampling had an elevated car-
diac troponin concentration. Second, age and
multimorbidity were important factors associated withcardiac troponin concentration. Nearly half of all patients
older than the age of 80 or with greater than 3 comorbid
conditions had an elevated cardiac troponin concentration.
Third, elevated cardiac troponin concentration was associ-
ated with adverse physiology at presentation. Age, serum
creatinine, hemodynamic compromise, and hypoxia were
strong predictors of an elevated cardiac troponin. Finally,
most patients with elevated cardiac troponin were admitted
into hospital, and every doubling in troponin concentration
was associated with mortality independent of age, sex, renal
function, and adverse physiology.
To our knowledge, this is the first study to evaluate the
determinants of elevated cardiac troponin in consecutive
patients Emergency Department patients without suspected
acute coronary syndrome with several important strengths
in the study design. We used a consecutive patient popula-
tion attending the Emergency Department who underwent
blood sampling to minimize selection bias. In comparison,
previous studies have evaluated the frequency of type 2
myocardial infarction and myocardial injury only in
patients who had troponin testing clinically requested.10,18
We also used a clinically available high-sensitivity troponin
I assay with excellent precision to measure cardiac tropo-
nin. This assay has superior analytical performance com-
pared to previous generations of cardiac troponin assays
with a limit of detection 10-fold lower than contemporary
sensitive assays.19,20 Finally, to ensure robust follow-up of
patients, we used comprehensive local and national death
registries.8,12
In our study, elevated cardiac troponin concentration
was common in patients without suspected acute coronary
syndrome in whom troponin testing was not requested by
the attending clinician. Age and admission physiology were
the strongest independent factors associated with elevated
troponin concentrations. Although elevated cardiac tropo-
nins are specific for indicating damage to the myocardium,
they are not specific for the etiology of injury. As such,
many acute and chronic pathological conditions are associ-
ated with elevated cardiac troponins.20,21 Perhaps
Table 1 Baseline Characteristics of Patients Stratified by High-Sensitivity Cardiac Troponin Concentration
All (n = 918) Group 1 (n = 316) Group 2 (n = 236) Group 3 (n = 252) Group 4 (n = 114) P-value
Range of troponin concentration, ng/L
Males ≤3 3 to 6 6 to 34 >34
Females ≤1 2 to 4 4 to 16 >16
Male sex 426 (46.4) 156 (49.4) 101 (42.8) 127 (50.4) 42 (36.8) 0.043
Age (years) 53.0 § 23.0 34.0 § 13.1 50.5 § 17.9 67.9 § 18.2 77.6 § 16.5 <0.001
Chest pain 75 (8.3) 24 (7.7) 18 (7.7) 21 (8.4) 12 (10.7) 0.776
Risk factors
Smoker 258 (33.2) 102 (37.6) 73 (36.5) 58 (27.0) 25 (27.8) 0.04
Ex-smoker 119 (15.3) 11 (4.1) 21 (10.5) 61 (28.2) 26 (28.9) <0.001
Hypertension 257 (28.4) 16 (5.2) 54 (23.1) 116 (46.6) 71 (62.8) <0.001
Hyperlipidemia 230 (25.4) 16 (5.2) 49 (20.9) 109 (43.8) 56 (49.1) <0.001
Family history 9 (1.0) 1 (0.3) 3 (1.3) 3 (1.2) 2 (1.8) 0.491
Past medical history
Ischemic heart disease 127 (14.0) 9 (2.9) 18 (7.7) 62 (24.9) 38 (33.3) <0.001
Myocardial infarction 61 (6.7) 5 (1.6) 7 (3.0) 31 (12.4) 18 (15.8) <0.001
Cerebrovascular disease 83 (9.2) 3 (1.0) 17 (7.3) 37 (14.9) 26 (22.8) <0.001
Peripheral vascular disease 43 (4.7) 4 (1.3) 5 (2.1) 19 (7.6) 15 (13.2) <0.001
Diabetes 81 (8.9) 13 (4.2) 18 (7.7) 35 (13.9) 15 (13.2) <0.001
Previous revascularization
PCI 28 (3.1) 4 (1.3) 5 (2.1) 13 (5.2) 6 (5.3) 0.022
CABG 19 (2.1) 0 (0.0) 1 (0.4) 9 (3.6) 9 (7.9) <0.001
Admission physiological parameters
Medium or high risk NEWS (≥5) 34 (5.7) 5 (2.4) 4 (2.7) 9 (5.5) 16 (19.5) <0.001
Respiratory rate (bpm) 18.3 § 4.3 17.6 § 3.7 17.3 § 3.0 18.5 § 3.8 21.4 § 6.5 <0.001
Temperature (˚C) 36.9 § 0.9 36.8 § 0.8 36.8 § 0.8 37.0 § 0.9 37.1 § 1.2 0.013
Pulse rate (bpm) 87.7 § 22.1 85.8 § 19.0 86.1 § 20.4 87.6 § 22.7 95.9 § 28.8 0.001
Systolic BP (mm Hg) 130.5 § 22.3 127.0 § 16.7 130.4 § 21.8 134.9 § 25.5 130.1 § 26.8 0.003
Oxygen saturations (%) 96.8 § 3.0 97.9 § 1.8 97.1 § 2.1 96.0 § 3.3 95.1 § 4.7 <0.001
On oxygen 52 (6.3) 4 (1.5) 6 (2.8) 19 (8.3) 23 (21.9) <0.001
Consciousness 0.01
Alert 880 (96.6) 306 (98.1) 227 (97.0) 243 (96.8) 104 (91.2)
Verbal 14 (1.5) 3 (1.0) 5 (2.1) 1 (0.4) 5 (4.4)
Pain 7 (0.8) 2 (0.6) 0 (0.0) 4 (1.6) 1 (0.9)
Unresponsive 10 (1.1) 1 (0.3) 2 (0.9) 3 (1.2) 4 (3.5)
Killip class <0.001
0 6 (0.7) 1 (0.3) 0 (0.0) 2 (0.8) 3 (2.7)
1 819 (90.8) 304 (99.0) 222 (95.7) 212 (84.8) 81 (71.7)
2 65 (7.2) 2 (0.7) 9 (3.9) 30 (12.0) 24 (21.2)
3 11 (1.2) 0 (0.0) 1 (0.4) 6 (2.4) 4 (3.5)
4 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9)
Hematology and biochemistry
Hemoglobin (g/dL) 13.3 § 2.0 13.9 § 1.5 13.5 § 1.7 12.9 § 2.1 12.1 § 2.4 <0.001
Creatinine (mg/dL) 0.96 § 0.74 0.80 § 0.16 0.88 § 0.78 1.07 § 0.90 1.30 § 1.00 <0.001
Urea (mg/dL) 5.9 § 3.7 4.4 § 1.5 5.1 § 2.4 7.0 § 4.1 9.7 § 5.5 <0.001
Admission drugs
Aspirin 130 (14.5) 7 (2.3) 19 (8.2) 66 (27.0) 38 (33.9) <0.001
Clopidogrel 62 (6.9) 5 (1.6) 10 (4.3) 33 (13.5) 14 (12.5) <0.001
Beta-blockers 109 (12.1) 9 (2.9) 24 (10.3) 45 (18.4) 31 (27.7) <0.001
ACE-I/ARB 143 (15.9) 9 (2.9) 34 (14.7) 63 (25.8) 37 (33.0) <0.001
Statin 192 (21.4) 13 (4.2) 43 (18.5) 91 (37.3) 45 (40.2) <0.001
Warfarin 35 (3.9) 1 (0.3) 7 (3.0) 16 (6.6) 11 (9.9) <0.001
PPI 184 (20.5) 28 (9.0) 52 (22.4) 65 (26.6) 39 (34.8) <0.001
Admission ECG
ST elevation 5 (1.0) 1 (0.6) 2 (1.7) 0 (0.0) 2 (2.3) 0.261
ST depression 9 (1.7) 0 (0.0) 1 (0.8) 2 (1.2) 6 (6.9) 0.001
T-wave inversion 34 (6.5) 3 (2.0) 6 (5.0) 16 (10.0) 9 (10.3) 0.012
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Table 1 (Continued)
All (n = 918) Group 1 (n = 316) Group 2 (n = 236) Group 3 (n = 252) Group 4 (n = 114) P-value
New LBBB 5 (1.0) 0 (0.0) 0 (0.0) 1 (0.6) 4 (4.6) 0.002
Old LBBB 13 (2.5) 0 (0.0) 0 (0.0) 8 (5.0) 5 (5.7) 0.002
RBBB 15 (2.9) 2 (1.3) 1 (0.8) 7 (4.4) 5 (5.7) 0.073
Outcomes
Admitted to hospital 512 (56.2) 128 (41.0) 119 (50.6) 169 (67.6) 96 (84.2) <0.001
30-day death 32 (3.5) 2 (0.6) 1 (0.4) 7 (2.8) 22 (19.3) <0.001
1-year death 102 (11.1) 6 (1.9) 13 (5.5) 40 (15.9) 43 (37.7) <0.001
Values are n (%) or mean § SD.
ACE-I/ARB = angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BP = blood pressure; bpm = breaths/beats per minute; CABG = coro-
nary artery bypass grafting; ECG = electrocardiogram; LBBB = left bundle branch block; NEWS = National Early Warning Score; PCI = percutaneous coronary
intervention; PPI = proton pump inhibitor; RBBB = right bundle branch block.
Lee et al High-Sensitivity Cardiac Troponin in the Emergency Department 110.e14unsurprisingly, elevated cardiac troponin concentrations are
common in a critical-care setting, and likely to be second-
ary to multiple mechanisms.22 Potential mechanisms of
injury include direct toxicity, hemodynamic compromise,
and, in some cases, increased thrombogenicity precipitating
a type 1 myocardial infarction. Myocardial oxygen supply-
demand imbalance is a major factor in the critically ill, and
both hypotension and increased metabolic demand are cor-
related with troponin concentrations.23 In addition, elevated
cardiac troponin are also associated with inflammatory
cytokines that may cause direct myocardial toxicity.24−27
So, what information do cardiac troponin levels convey
in patients attending the emergency department? There are
many cardiac and noncardiac conditions unrelated to type 1
myocardial infarction that may result in elevated troponin
concentrations. The universal definition of myocardial
infarction acknowledges this diversity by classifying ele-
vated troponin levels in such instances as either type 2 myo-
cardial infarction or myocardial injury.16 Our analysis
confirms previous studies demonstrating close associations
among troponin concentrations, acute illness severity, and
increased risk of death.8,22 These associations remain
robust and independent of known important confoundersTable 2 Logistic Regression Models for Determinants of Elevated Ca
Department
Variable Model 1, OR (95% CI)
Age, per 10 years 2.13 (1.78 − 2.62)*
Creatinine, per 0.11 mg/dL 1.03 (1.00 − 1.07)y
Sex (Male) 0.56 (0.31 − 1.01)
NEWS, per 1 unit 1.55 (1.33 − 1.83)*
Comorbidity
None (referent) —
1 —
2 —
Over 3 —
AIC (model fit) 325
AIC =Akaike Information Criterion; CI, confidence interval; NEWS = National Ea
*p value <0.001.
yp value <0.05.including age, sex, multimorbidity, renal function, and
adverse physiological measures.
Our study has several broad clinical implications when
adopting high-sensitivity assays. First, the prevalence of
elevated high-sensitivity cardiac troponin is high in patients
attending the emergency department without suspected
acute coronary syndrome. High-sensitivity assays were
introduced into clinical practice in Australasia, Canada, and
Europe in 2010, yet the first high-sensitivity assay has only
recently received approval from the U.S. Food and Drug
Administration for use in the United States.20,28 Although
lowering the diagnostic threshold of cardiac troponin using
more sensitive assays does not result in an increased num-
ber of tests per se, it does result in an increased proportion
of “positive” results and an increased detection of nonacute
coronary syndrome pathologies.2,29 Indiscriminate troponin
testing in patients without signs or symptoms consistent
with acute coronary syndrome should be discouraged
because it is likely to increase the challenges involved in
interpreting troponin test results for the attending clinician.
Second, although troponin elevations detected with these
novel assays identify patients at risk of death, there is cur-
rently no evidence that these patients with an elevatedrdiac Troponin in Unselected Patients Attending the Emergency
Model 2, OR (95% CI) Model 3, OR (95% CI)
- 2.07 (1.70 − 2.58)*
1.03 (1.00 − 1.06) 1.03 (1.00 − 1.06)y
0.38 (0.21 − 0.67)* 0.52 (0.27 − 0.94)y
1.57 (1.36 − 1.83)* 1.56 (1.33 − 1.84)*
1 1
4.59 (2.37 − 8.99)* 1.24 (0.58 − 2.63)
4.49 (2.07 − 9.62)* 0.95 (0.40 − 2.25)
10.11 (4.3 − 23.81)* 2.16 (0.85 − 5.47)
386 324
rly Warning Score; OR = odds ratio.
Figure 2 (A) Cumulative incidence for all-cause mortality in patients in whom cardiac troponin was not requested by the attending
clinician, stratified by cardiac troponin concentration at presentation. (B) Association between cardiac troponin concentration and
hazard ratio for death. Estimates obtained from a Cox regression model with penalized smoothing splines and adjusted for age, sex,
and renal function. Rug plot shows density of data for given value of cardiac troponin.
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Lee et al High-Sensitivity Cardiac Troponin in the Emergency Department 110.e16troponin who do not have a diagnosis of type 1 myocardial
infarction would benefit from any additional therapy.8
Third, elevated troponin concentrations reflect cardiac dam-
age analogous to creatinine for acute kidney injury or hyp-
oxia in the context of acute lung injury. As such, elevated
cardiac troponin concentrations not resulting from a pri-
mary coronary pathology (ie type 1 myocardial infarction)
identify patients with an acute illness and adverse physiol-
ogy. In our cohort, most patients with undisclosed elevated
cardiac troponin concentration were admitted to hospital.
Two patients (0.2%) were adjudicated as type 1 myocardial
infarction of whom one patient was a 94-year old man diag-
nosed as a late presentation myocardial infarction clinically
and received palliative care in the hospital, highlighting
that the attending clinicians were good at discriminating
those patients who required further in-patient investigation
and care.
Limitations
There were several limitations in our study. Our cohort
originated from a single center. However, our Emergency
Department is in a large tertiary center providing acute
medical care to the southeast of Scotland. We would not
therefore envisage our patient population to be different
from other Emergency Departments and consider our
results and interpretation generalizable. However, we
acknowledge that this study was conducted during the sum-
mer, and therefore, the study population may not be repre-
sentative of the patient population presenting to Emergency
Departments during the winter months. We also did not
have serial troponin concentrations and are not able to com-
ment on the whether there was an acute rise or fall in tropo-
nin concentrations. As such, our classification of the
myocardial injury is based on a single baseline sample and
may have underestimated the prevalence of myocardial
infarction as a result of misclassification. Moreover, we
only measured troponin concentration in patients who had
blood sampling performed by the attending clinician.
Although this might have introduced some confounding by
indication, we believe this ensured that our study is repre-
sentative of the broad population of patients presenting to
the Emergency Department who were sufficiently unwell to
require blood testing. It is in this group of patients in which
diagnostic uncertainty may arise should troponin testing is
requested indiscriminately.CONCLUSION
This is the first study that has evaluated high-sensitivity car-
diac troponin concentrations in consecutive patients attend-
ing an Emergency Department without suspected acute
coronary syndrome, in whom blood sampling was under-
taken by the attending physician. Our analysis shows that
elevated cardiac troponin concentrations are common in
patients without suspected acute coronary syndrome. Tro-
ponin concentration is strongly associated with age, comor-
bidities, adverse physiology at presentation, and subsequentpoorer outcomes. As high-sensitivity cardiac troponin
assays are adopted more widely, an improved understand-
ing of the prevalence, determinants, and clinical associa-
tions of cardiac troponin in patients without acute coronary
syndrome is required to ensure that test results are inter-
preted correctly and the subsequent clinical management is
appropriate.References
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Supplementary Table 1 Parameters and Scoring System of the National Early Warning Score (NEWS)
Points 3 2 1 0 1 2 3
Physiological parameter
Respiratory rate, breaths per minute ≤8 − 9 to 11 12 to 20 − 21 to 24 ≥25
Oxygen saturations, % ≤91 92 to 93 94 to 95 ≥96 − −
Any supplemental oxygen − Yes − No − − −
Temperature, oC ≤35.0 35.1 to 36.0 36.1 to 38.0 38.1 to 39 ≥39.1 −
Systolic blood pressure, mmHg ≤90 91 to 100 101 to 110 111 to 219 − − −
Heart rate, beats per minute ≤40 − 41 to 50 51 to 90 91 to 110 111 to 130 ≥131
Consciousness − − − Alert − Voice, Pain or Unresponsive −
Supplementary Figure 1 Flow diagram of the study population of unselected patients attending
the Emergency Department
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Supplementary Table 2 Baseline Characteristics of Consecutive Patients in the Emergency Department With and Without Cardiac Tropo-
nin Testing Requested by the Attending Clinician
Troponin requested by clinician
All (n=1,054) No (n=918) Yes (n=136) P-value
Male sex 505 (47.9) 426 (46.4) 79 (58.1) 0.014
Age (years) 54.5 § 22.6 53.0 § 23.0 64.9 § 16.4 <0.001
Elevated cardiac troponin* 144 (13.7) 114 (12.4) 30 (22.1) <0.001
Presenting complaint
Chest pain, n (%) 183 (17.6) 75 (8.3) 108 (79.4) <0.001
Abdominal pain, n (%) 160 (15.2) 156 (17.0) 4 (2.9) <0.001
Fall/collapse, n (%) 158 (15.0) 151 (16.4) 7 (5.1) 0.001
Dyspnea, n (%) 57 (5.4) 51 (5.6) 6 (4.4) 0.728
Confusion, n (%) 18 (1.7) 17 (1.9) 1 (0.7) 0.56
Dizziness, n (%) 14 (1.3) 13 (1.4) 1 (0.7) 0.806
Other, n (%) 464 (44.0) 455 (49.6) 9 (6.6) <0.001
Risk factors
Smoker 299 (33.1) 258 (33.2) 41 (32.5) 0.957
Ex-smoker 154 (17.1) 119 (15.3) 35 (27.8) 0.001
Hypertension 337 (32.4) 257 (28.4) 80 (59.3) <0.001
Hyperlipidemia 299 (28.7) 230 (25.4) 69 (51.5) <0.001
Family history 26 (2.5) 9 (1.0) 17 (12.7) <0.001
Past medical history
Ischemic heart disease 193 (18.5) 127 (14.0) 66 (48.9) <0.001
Myocardial infarction 109 (10.5) 61 (6.7) 48 (35.6) <0.001
Cerebrovascular disease 99 (9.5) 83 (9.2) 16 (11.9) 0.403
Peripheral vascular disease 50 (4.8) 43 (4.7) 7 (5.2) 0.992
Supplementary Figure 2 Density plot for the distribution of cardiac troponin I concentration in unse-
lected patients attending the Emergency Department stratified by sex with blue as males and red as
females.
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Supplementary Table 2 (Continued)
Troponin requested by clinician
All (n=1,054) No (n=918) Yes (n=136) P-value
Diabetes mellitus 106 (10.1) 81 (8.9) 25 (18.5) 0.001
Previous revascularisation
PCI 52 (5.0) 28 (3.1) 24 (17.8) <0.001
CABG 32 (3.1) 19 (2.1) 13 (9.6) <0.001
Admission physiological parameters
Respiratory rate (bpm) 18.2 § 4.2 18.3 § 4.3 17.8 § 3.4 0.253
Temperature (oC) 36.9 § 0.9 36.9 § 0.9 36.6 § 0.6 0.003
Pulse rate (bpm) 86.9 § 22.3 87.7 § 22.1 81.8 § 23.0 0.008
Systolic BP (mmHg) 130.5 § 22.2 130.5 § 22.3 130.8 § 21.9 0.887
Oxygen saturations (%) 96.8 § 2.9 96.8 § 3.0 96.7 § 2.2 0.7
On oxygen 62 (6.6) 52 (6.3) 10 (8.1) 0.598
Consciousness 0.515
Alert 1014 (96.8) 880 (96.6) 134 (98.5)
Verbal 14 (1.3) 14 (1.5) 0 (0.0)
Pain 8 (0.8) 7 (0.8) 1 (0.7)
Unresponsive 11 (1.1) 10 (1.1) 1 (0.7)
Killip class 0.012
0 6 (0.6) 6 (0.7) 0 (0.0)
1 930 (89.7) 819 (90.8) 111 (82.2)
2 85 (8.2) 65 (7.2) 20 (14.8)
3 15 (1.4) 11 (1.2) 4 (3.0)
4 1 (0.1) 1 (0.1) 0 (0.0)
Hematology and biochemistry
Hemoglobin (g/dL) 13.3 § 1.9 13.3 § 2.0 13.2 § 1.7 0.590
Creatinine (mg/dL) 0.97 § 0.72 0.96 § 0.74 1.04 § 0.58 0.207
Urea (mg/dL) 6.1 § 3.7 5.9 § 3.7 6.8 § 3.8 0.017
Troponin I (ng/L) 3.0 [2.0, 10.0] 3.0 [2.0, 9.0] 5.0 [3.0, 19.5] <0.001
Admission drugs
Aspirin 180 (17.5) 130 (14.5) 50 (37.6) <0.001
Clopidogrel 81 (7.9) 62 (6.9) 19 (14.3) 0.005
Beta-blockers 149 (14.5) 109 (12.1) 40 (30.1) <0.001
ACE-I/ARB 189 (18.3) 143 (15.9) 46 (34.6) <0.001
Statin 249 (24.2) 192 (21.4) 57 (42.9) <0.001
Warfarin 44 (4.3) 35 (3.9) 9 (6.8) 0.195
PPI 233 (22.6) 184 (20.5) 49 (36.8) <0.001
Admission electrocardiogram
ST elevation 13 (2.0) 5 (1.0) 8 (6.0) 0.001
ST depression 21 (3.2) 9 (1.7) 12 (9.0) <0.001
T-wave inversion 58 (8.9) 34 (6.5) 24 (18.0) <0.001
New LBBB 11 (1.7) 5 (1.0) 6 (4.5) 0.014
Old LBBB 17 (2.6) 13 (2.5) 4 (3.0) 0.982
RBBB 21 (3.2) 15 (2.9) 6 (4.5) 0.501
Management
Chest pain nurse referral 36 (3.4) 5 (0.5) 31 (22.8) <0.001
Cardiology referral 50 (4.8) 14 (1.5) 36 (26.5) <0.001
Admitted to hospital 609 (58.2) 512 (56.2) 97 (71.3) 0.001
Echocardiogram 17 (1.6) 5 (0.5) 12 (8.8) <0.001
Coronary angiogram 17 (1.6) 2 (0.2) 15 (11.0) <0.001
PCI 10 (1.0) 0 (0.0) 10 (7.4) <0.001
CABG 1 (0.1) 0 (0.0) 1 (0.7) 0.27
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Supplementary Table 2 (Continued)
Troponin requested by clinician
All (n=1,054) No (n=918) Yes (n=136) P-value
Discharge drugs
Aspirin 192 (18.8) 131 (14.7) 61 (45.5) <0.001
Clopidogrel 102 (10.0) 69 (7.8) 33 (24.6) <0.001
Beta-blockers 152 (14.9) 106 (11.9) 46 (34.3) <0.001
ACEI/ARB 181 (17.7) 134 (15.1) 47 (35.1) <0.001
Statin 256 (25.0) 192 (21.5) 64 (47.8) <0.001
Warfarin 44 (4.3) 33 (3.7) 11 (8.2) 0.03
Proton pump inhibitor 246 (24.0) 193 (21.7) 53 (39.6) <0.001
Values are n (%), mean § SD or median [IQR]
Abbreviations: bpm=breaths/beats per minute; BP=blood pressure; PCI= percutaneous coronary intervention, CABG=coronary artery bypass grafting, ACE-
I/ARB=angiotensin converting enzyme inhibitor/ angiotensin receptor blocker, PPI=proton pump inhibitor
*Consists of all patients with troponin levels above the 99th percentile upper reference limit using sex specific diagnostic thresholds including those
further classified as type 1 and type 2 myocardial infarction
Supplementary Table 3 Case Series of Patients Classified as Type 1 or Type 2 Myocardial Infarction in Whom the Attending Clinician Did
Not Request Cardiac Troponin
Age Sex Classification Presenting
complaint
Known IHD TnI, ng/L Ischemia on
ECG
Admitted Clinical details
94 M Type 1 Chest pain No 1,377 Yes Yes Late presentation myocardial infarc-
tion, not for escalation of care,
died in hospital
44 M Type 1 Chest pain No 132 No No Atypical history of chest pain
65 M Type 2 Breathlessness No 46 Yes Yes Patient with multiple comorbidities
and admitted with shortness of
breath secondary to exacerbation
of COPD
94 F Type 2 Chest pain No 24 No Yes Admitted with fast ventricular
response to atrial fibrillation and
associated chest tightness
72 M Type 2 Chest pain No 36 Yes Yes Admitted with fast ventricular
response to atrial fibrillation and
associated chest pain with rate
related left bundle branch block
Supplementary Table 4 Presenting Complaint in Patients
Without Suspected Acute Coronary Syndrome and Cardiac Tropo-
nin Concentrations >99th Centile
Presenting complaint Number (n = 114) Percentage
Fall/Collapse 39 34.2%
Chest pain 11 9.6%
Dyspnea 10 8.8%
Abdominal pain 8 7.0%
Dizziness 4 3.5%
Confusion 3 2.6%
Other 39 34.2%
Supplementary Table 5 Primary Clinical Diagnostic Category
of Patients with Cardiac Troponin Concentrations >99th Centile
Diagnostic category Number (n = 114) Percentage
Infective / sepsis 31 27%
Mechanical fall 15 13%
Other 14 12%
Cardiac* 12 11%
Respiratoryy 11 10%
Trauma / Orthopaedic 10 9%
Gastrenterology / hepatology 7 6%
Renal 6 5%
Surgical 5 4%
Neurological 3 3%
*In patients with a cardiac diagnosis, atrial fibrillation accounted
for the majority (n=8).
yThese refer to respiratory diagnoses other than pneumonia which
was included within the Infective/sepsis category.
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Supplementary Table 6 Primary Cause of Death for All Patients
Without Suspected Acute Coronary Syndrome at 1 Year Follow-Up
Death category Number (n = 102) Percentage
Sepsis 20 19.6%
Cancer 12 11.8%
Respiratory 7 6.9%
Gastrointestinal 6 5.9%
Cardiac 5 4.9%
Stroke 3 2.9%
Vascular 3 2.9%
Renal 3 2.9%
Other 3 2.9%
Unknown 40 39.2%
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